checkAd

    Guerbet  166  0 Kommentare 2019 annual results

    2019 annual results

    •  Revenue growth to €816.9 million in line with objectives
      • Revenue of €816.9 million, a 3.5% increase
      • Revenue of €805.6 million at constant exchange rates, up 2%
    • EBITDA of €111.5 million, increasing year over year on a like-for-like basis
    • Strong improvement in free cash flow to €28.3 million and net debt reduced to €280.5 million (excluding IFRS 16 impact) thanks to a significant reduction in inventories
    • 2020: Continuation of the value-creation strategy initiated by the Group
      • Significant growth in the Interventional Imaging segment
      • Continuation of the “Cost to Win” savings plan
      • Finalisation of gadopiclenol phase III
      • Continuation of the inventory reduction plans 
    • 2020 outlook: Uncertainty related to the measures taken to combat the COVID-19 epidemic despite a minor impact on Guerbet’s activity observed to date


    Villepinte, 24 March 2020 – Guerbet (FR0000032526), a global leader in medical imaging, is announcing its consolidated annual results for 2019.

    On 24 March 2020, the Board of Directors approved the financial statements for the financial year ended 31 December 2019. The audit procedures have been completed, and the statutory auditors’ report is being prepared.


    Both business segment growing

    Reported revenue of €816.9 million was up 3.5% from 2018, including a favourable forex impact of €11.3 million. Revenue was up 2.0% at €805.6 million at constant exchange rates(1). Excluding the impact of the decrease in activity related to a subcontract inherited from the CMDS activities, revenue growth at constant exchange rates would have been 3.7% over the 2019 financial year.

    Diagnostic Imaging sales increased to €711.0 million at constant exchange rates (+3.0%) and €719.5 million at current exchange rates.

    - Sales in the MRI(2) segment totalled €271.4 million at constant exchange rates and like-for-like period and scope (€275.0 million at current exchange rates) compared with sales of €272.0 million in 2018. In 2019, activity suffered from the planned withdrawal of Optimark from the market. Excluding Optimark, MRI sales at constant exchange rates were up 1.6%.

    Seite 1 von 6


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Guerbet 2019 annual results 2019 annual results  Revenue growth to €816.9 million in line with objectives Revenue of €816.9 million, a 3.5% increaseRevenue of €805.6 million at constant exchange rates, up 2% EBITDA of €111.5 million, increasing year over year on a …